

Express Mail No. EV333997817US

INFORMATION STATEMENT UNDER 37 C.F.R. § 1.97(e)

Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attorney Docket	STAN-270US2
First Named Inventor	WEISSMAN, IRVING L.
Application Number	10/729,548
Confirmation No.	4320
Filing Date	December 5, 2003
Group Art Unit	1644
Examiner Name	

Title: "PROTECTION OF STEM CELLS FROM

CYTOTOXIC AGENTS BY MODULATION OF BETA-

CATENIN SIGNALING PATHWAYS"

Sir:

Applicants submit herewith patents and/or publications which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. While this Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. A listing of patents and/or publications is shown on enclosed Form PTO-SB/08A and a copy of each patent and/or publication is also enclosed.

Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

The Examiner is requested to make the citations listed on the enclosed PTO-SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO-SB/08A, indicating the references have been considered and made of record herein.

No fee is believed due as this statement is being submitted within three months of the mailing date of the enclosed foreign communication. However, if it is determined that fees are required, the Commissioner is hereby authorized to charge any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 50-0815, Order No. STAN-270US2.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date:

May 10, 2004

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200

Menlo Park, CA 94025 Telephone: (650) 327-3400

Facsimile: (650) 327-3231

Bv:

amela /. Sherwood, Reg. No. 36,67

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known		
					Application Number	10/729,548
INFORMATION DISCLOSURE					Filing Date	December 5, 2003
STATEMENT BY APPLICANT				First Named Inventor	WEISSMAN, IRVING L.	
					Art Unit	1644
(use as many sheets as necessary)				Examiner Name		
Sheet	1	of		1	Attorney Docket Number	STAN-270US2

			U.S. PATENT D	OCUMENTS	
Examiner Initials'	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
i i i i i i i i i i i i i i i i i i i	-	US-	MM-DD-YYYY	Applicant of Cited Document	Figures Appear
		US-			

		FOREIG	N PATENT DO	CUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials' No.1		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T ⁶
		OTHER PRIOR ART—N	ON PATENT LIT	FERATURE DOCUMENT	S	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),			T ²	
		DASGUPTA et al., MU TRANSCRIPTION COMPLE AND DIFFERENTIATION, D	EXES DURIN	IG HAIR FOLLICLE	E DEVELOPMENT	
.*	XU et al., WISP-1 IS A WNT-1-AND ß-CATENIN-RESPONSIVE ONCOGENE, Genes & Dev., 2000, 14: 585-595					
		ZHU et al., ß-CATENIN POTENTIAL OF HUMAN E OF INTERCELLULAR ADHE	EPIDERMAL	KERATINOCYTES	INDEPENDENTLY	

Examiner	Date	
Signature	 Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

- If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.